Generated by All in One SEO v5.0.0.1, this is an llms.txt file, used by LLMs to index the site.

# MFX

The Cyto Engine

## Sitemaps

- [XML Sitemap](https://mfx.bio/sitemap.xml): Contains all public & indexable URLs for this website.

## Posts

- [Advanced manufacturing and industrialisation of the CGT sector – What’s next?](https://mfx.bio/advanced-manufacturing-and-industrialisation-of-the-cgt-sector/) - [et_pb_section fb_built=”1″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.2″ _module_preset=”default” header_text_align=”center” header_text_color=”#010443″ header_font_size=”34px” header_line_height=”1.3em” global_colors_info=”{}”]Advanced manufacturing and industrialisation of the CGT sector – What’s next?[/et_pb_text][et_pb_text ul_position=”inside” _builder_version=”4.27.2″ _module_preset=”default” text_font=”Manrope|300|||||||” text_font_size=”20px” text_line_height=”1.4em” custom_padding=”||0px|||” hover_enabled=”0″ global_colors_info=”{}” header_line_height=”1.3em” header_2_line_height=”1.3em” header_3_line_height=”1.3em” sticky_enabled=”0″ header_4_line_height=”1.3em” header_5_line_height=”1.3em” header_6_line_height=”1.3em”] We sat down with Katy, our Chief Scientific Officer, to
- [The Promise and Challenges of Regulatory T Cell Therapy: A New Frontier in Immunotherapy](https://mfx.bio/the-promise-and-challenges-of-regulatory-t-cell-therapy/) - [et_pb_section fb_built=”1″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.2″ _module_preset=”default” header_text_align=”center” header_text_color=”#010443″ header_font_size=”34px” header_line_height=”1.3em” global_colors_info=”{}”]The Promise and Challenges of Regulatory T Cell Therapy: A New Frontier in Immunotherapy[/et_pb_text][et_pb_text ul_position=”inside” _builder_version=”4.27.2″ _module_preset=”default” text_font=”Manrope|300|||||||” text_font_size=”20px” text_line_height=”1.3em” custom_padding=”||0px|||” global_colors_info=”{}”] In recent years, regulatory T cell (Treg) therapy has emerged as a ground breaking approach
- [The Best Cell and Gene Therapy Conferences of 2025](https://mfx.bio/mfx-best-cell-and-gene-conferences-2025/) - [et_pb_section fb_built=”1″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.2″ _module_preset=”default” header_text_align=”center” header_text_color=”#010443″ header_font_size=”34px” header_line_height=”1.3em” global_colors_info=”{}”]The Best Cell and Gene Therapy Conferences of 2025[/et_pb_text][et_pb_text _builder_version=”4.27.2″ _module_preset=”default” text_font=”Manrope|300|||||||” text_font_size=”20px” text_line_height=”1.3em” global_colors_info=”{}”]As the new year begins, we asked our VP of Commercial, Lindsey Clarke, to share her top picks for the coming year and
- [Celebrating a Year of Innovation and Growth](https://mfx.bio/mfx-year-of-innovation-and-growth/) - [et_pb_section fb_built=”1″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.2″ _module_preset=”default” header_text_align=”center” header_text_color=”#010443″ header_font_size=”34px” header_line_height=”1.3em” global_colors_info=”{}”]Celebrating a Year of Innovation and Growth: MFX’s Key Milestones in 2024 [/et_pb_text][et_pb_text _builder_version=”4.27.2″ _module_preset=”default” text_font=”Manrope|300|||||||” text_font_size=”20px” text_line_height=”1.3em” global_colors_info=”{}”]and a look ahead to how 2025 is shaping up! As we kick off 2025, we wanted to take a
- [MFX's summer of students](https://mfx.bio/mfxs-summer-of-students/) - [et_pb_section fb_built=”1″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.2″ _module_preset=”default” header_text_align=”center” header_text_color=”#010443″ header_font_size=”34px” header_line_height=”1.3em” global_colors_info=”{}”]MFX’s summer of students[/et_pb_text][et_pb_text _builder_version=”4.27.2″ _module_preset=”default” text_font=”Manrope|300|||||||” text_font_size=”20px” text_line_height=”1.3em” global_colors_info=”{}”]Why investing time in the next generation helps give us new insights into our own technologies. A common theme that has come up within the team at MFX
- [From cell culture to cell therapy - the biggest challenges of growing cells ex vivo](https://mfx.bio/from-cell-culture-to-cell-therapy-the-biggest-challenges-of-growing-cells-ex-vivo/) - [et_pb_section fb_built=”1″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.2″ _module_preset=”default” header_text_align=”center” header_text_color=”#010443″ header_font_size=”34px” header_line_height=”1.3em” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]From cell culture to cell therapy – the biggest challenges of growing cells ex vivo[/et_pb_text][et_pb_text _builder_version=”4.27.2″ _module_preset=”default” text_font=”Manrope|300|||||||” text_font_size=”20px” text_line_height=”1.3em” header_3_line_height=”1.2em” global_colors_info=”{}”]During the development of the Cyto Engine platform we interviewed over 100 experts in
- [Cutting the cost of CAR-Ts – Innovative strategies to make cell therapies more affordable](https://mfx.bio/cutting-the-cost-of-car-ts-innovative-strategies-to-make-cell-therapies-more-affordable/) - [et_pb_section fb_built=”1″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.2″ _module_preset=”default” header_text_align=”center” header_text_color=”#010443″ header_font_size=”34px” header_line_height=”1.3em” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Cutting the cost of CAR-Ts – Innovative strategies to make cell therapies more affordable[/et_pb_text][et_pb_text _builder_version=”4.27.2″ _module_preset=”default” text_font=”Manrope|300|||||||” text_font_size=”20px” text_line_height=”1.3em” global_colors_info=”{}”]T cells are the most extensively studied cell type in the development of cell therapies, constituting
- [Embracing Inclusivity: The CGT Circle X Pride - A Recap of The CGT Circle’s First-Ever Workshop](https://mfx.bio/2008-2/) - [et_pb_section fb_built=”1″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.2″ _module_preset=”default” header_text_align=”center” header_text_color=”#010443″ header_font_size=”34px” header_line_height=”1.3em” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]Embracing Inclusivity: The CGT Circle X Pride – A Recap of The CGT Circle’s First-Ever Workshop[/et_pb_text][et_pb_text _builder_version=”4.27.2″ _module_preset=”default” text_font=”Manrope|300|||||||” text_font_size=”20px” text_line_height=”1.3em” global_colors_info=”{}”]Last month The CGT Circle held it’s first ever workshop event at Stevenage Bioscience
- [The Best Cell and Gene Therapy Conferences of 2024](https://mfx.bio/the-best-cell-and-gene-therapy-conferences-of-2024/) - [et_pb_section fb_built=”1″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.24.0″ _module_preset=”default” header_text_align=”center” header_text_color=”#010443″ header_font_size=”34px” header_line_height=”1.3em” global_colors_info=”{}”]The Best Cell and Gene Therapy Conferences in 2024[/et_pb_text][et_pb_text _builder_version=”4.24.0″ _module_preset=”default” text_font=”Manrope|300|||||||” text_font_size=”20px” text_line_height=”1.3em” global_colors_info=”{}”]What are the best Cell and Gene Therapy conferences to attend in 2024? We asked our VP of Commercial Lindsey Clarke what her
- [How to Innovate? The MFX way](https://mfx.bio/how-to-innovate-the-mfx-way/) - [et_pb_section fb_built=”1″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.24.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.2″ _module_preset=”default” header_text_align=”center” header_text_color=”#010443″ header_font_size=”34px” header_line_height=”1.3em” global_colors_info=”{}”]How to Innovate? The MFX way[/et_pb_text][et_pb_text _builder_version=”4.27.2″ _module_preset=”default” text_font=”Manrope|300|||||||” text_font_size=”20px” text_line_height=”1.3em” global_colors_info=”{}”]Césaré Cejas, PhD gave a recent talk at the Bioengineering Symposium, a jointly organised event held by the Oxford University Bioengineering Society and Warwick BioSoc on
- [Analytical Scientist - Bioreactor Analytics and Validation](https://mfx.bio/analytical-scientist-bioreactor-analytics-and-validation/) - The Analytical Scientist - Bioreactor Analytics and Validation at MFX will be a key player in advancing the revolutionary bioprocessing platform for the Cell and Gene Therapy (CGT) market.
- [Engineering Project Manager](https://mfx.bio/engineering-project-manager/) - The Engineering Project Manager role will be project managing pre-production consumables and hardware and with the role transitioning to the managing products introduction into the Cell and Gene therapy marketplace.
- [Mechanical Design Engineer](https://mfx.bio/mechanical-design-engineer/) - The Mechanical Design Engineer role will span both the design of prototypes, rigs and also the production design of our products and will ensure best design practices to meet medical device and GMP standards where appropriate.
- [Data and Digitization – The key to better biology and more effective therapies](https://mfx.bio/blog-data-and-digitization/) - Goodbye paper. Digitizing data collection, analysis, and record keeping is the future of cell and gene therapies
- [Software Engineer](https://mfx.bio/jobs-software-engineer/) - The software engineer at MFX will be a key player in advancing the revolutionary bioprocessing platform for the Cell and Gene Therapy (CGT) market.
- [Making cell therapies comPATible with large scale manufacturing](https://mfx.bio/blog-making-cell-therapies-compatible-with-manufacturing/) - Without PATs, large-scale manufacturing of cell therapies isn't commercially viable
- [How do you solve a problem like scaling up microfluidics?](https://mfx.bio/blog-scaling-up-microfluidics/) - Can microfluidics really deliver clinically relevant numbers of cells for cell therapies?
- [Make your cells feel at home with microfluidics](https://mfx.bio/blog-make-your-cells-feel-at-home-with-microfluidics/) - Are your cell culture vessels truly providing an optimal environment for cell expansion?
- [Microfluidics- the perfect meeting-place for viruses and cells](https://mfx.bio/blog-microfluidics-the-perfect-meeting-place-for-viruses-and-cells/) - Viral transduction is currently a high-cost, low-yield process with conventional bioreactors
- [Scale up, look sharp – why analytics in large-scale cell therapy manufacture is so difficult](https://mfx.bio/blog-scale-up-look-sharp/) - CGTs developers need better analytics in their manufacturing platforms to refine processes and characterize their product
- [Why successful cell therapy processes need to scale both ways](https://mfx.bio/blog-why-cell-therapy-processes-need-to-scale-both-ways/) - A process for manufacture that can't be scaled down isn't beneficial if pre-clinical development needs to be revisited
- [Is innovation in automation enough to drive cell therapy manufacturing optimization?](https://mfx.bio/blog-innovation-in-automation-for-cgt-manufacturing/) - Robot arms and existing automated cell culture platforms won't be able to support the future needs of cell therapy manufacturing
- [Footprint size matters in cell and gene therapy manufacturing](https://mfx.bio/blog-footprint-size-matters-in-cgt-manufacturing/) - Footprint size matters in cell and gene therapy manufacturing
- [How to ensure a consistent cell expansion process](https://mfx.bio/blog-ensure-a-consistent-cell-expansion-process/) - Relying on endpoints doesn't give a true representation of the cell expansion process
- [New technologies, old methods- Why 99% of cell culture vessels will never scale](https://mfx.bio/blog-new-technologies-old-methods/) - Cell and gene therapy developers need to start thinking about scaling up earlier on in the process
- [99 problems in manual cell culture](https://mfx.bio/blog-99-problems-in-cell-research/) - Even the simple action of pipetting adds variability during manual cell processing

## Pages

- [MFX - The Cyto Engine](https://mfx.bio/) - Delivering the next generation of automated cell and gene therapy manufacturing platforms to bring precision medicine to patients
- [News](https://mfx.bio/news/) - Keep up to date with what we're up to at MFX
- [MFX is the Official Hardware Partner in the EcoCAR Consortium – An Innovate UK Sustainable Medicines Manufacturing Funded Collaboration](https://mfx.bio/news-press-releases/press-release-mfx-ecocar-2025/) - [et_pb_section fb_built=”1″ _builder_version=”4.18.0″ _module_preset=”default” background_color=”#010443″ background_image=”https://microfluidx.co.uk/wp-content/uploads/2022/09/analysis-gac5592752_19202-1.jpg” background_position=”top_center” background_vertical_offset=”51%” background_blend=”overlay” custom_padding=”48px||33px|||” global_colors_info=”{}”][et_pb_row _builder_version=”4.17.1″ _module_preset=”default” custom_margin=”-5px|auto||auto||” custom_padding=”5px|||||” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.17.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.18.0″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#FFFFFF” text_font_size=”55px” text_line_height=”1.3em” width=”100%” module_alignment=”left” custom_margin=”15px|||||” global_colors_info=”{}”] Press Releases [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.18.0″ _module_preset=”default” background_color=”#FFFFFF” custom_margin=”||-1px|||” custom_padding=”35px||55px|||” top_divider_height=”53px” top_divider_flip=”horizontal” bottom_divider_height=”47px” bottom_divider_flip=”horizontal” global_colors_info=”{}”][et_pb_row _builder_version=”4.18.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.18.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.2″ _module_preset=”default” text_font=”Lexend|500|||||||” text_text_color=”#010443″
- [News-press releases](https://mfx.bio/news-press-releases/) - View our latest press releases
- [MFX_New CSO_PR_18March2025](https://mfx.bio/news-press-releases/press-release-mfx-new-cso-2025/) - [et_pb_section fb_built=”1″ _builder_version=”4.18.0″ _module_preset=”default” background_color=”#010443″ background_image=”https://microfluidx.co.uk/wp-content/uploads/2022/09/analysis-gac5592752_19202-1.jpg” background_position=”top_center” background_vertical_offset=”51%” background_blend=”overlay” custom_padding=”48px||33px|||” global_colors_info=”{}”][et_pb_row _builder_version=”4.17.1″ _module_preset=”default” custom_margin=”-5px|auto||auto||” custom_padding=”5px|||||” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.17.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.18.0″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#FFFFFF” text_font_size=”55px” text_line_height=”1.3em” width=”100%” module_alignment=”left” custom_margin=”15px|||||” global_colors_info=”{}”] Press Releases [/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.18.0″ _module_preset=”default” background_color=”#FFFFFF” custom_margin=”||-1px|||” custom_padding=”35px||55px|||” top_divider_height=”53px” top_divider_flip=”horizontal” bottom_divider_height=”47px” bottom_divider_flip=”horizontal” global_colors_info=”{}”][et_pb_row _builder_version=”4.18.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.18.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.2″ _module_preset=”default” text_font=”Lexend|500|||||||” text_text_color=”#010443″
- [People](https://mfx.bio/people/) - Meet our leadership and advisory team
- [Data](https://mfx.bio/data/) - View our latest vacancies and help us develop the next generation of bioprocessing platforms
- [MFX_Tolemy_AA_05Dec2024](https://mfx.bio/news-press-releases/press-release-mfx-tolemy-aa-2024/) - [et_pb_section fb_built=”1″ _builder_version=”4.18.0″ _module_preset=”default” background_color=”#010443″ background_image=”https://microfluidx.co.uk/wp-content/uploads/2022/09/analysis-gac5592752_19202-1.jpg” background_position=”top_center” background_vertical_offset=”51%” background_blend=”overlay” custom_padding=”48px||33px|||” global_colors_info=”{}”][et_pb_row _builder_version=”4.17.1″ _module_preset=”default” custom_margin=”-5px|auto||auto||” custom_padding=”5px|||||” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.17.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.18.0″ _module_preset=”default” text_font=”|600|||||||” text_text_color=”#FFFFFF” text_font_size=”55px” text_line_height=”1.3em” width=”100%” module_alignment=”left” custom_margin=”15px|||||” global_colors_info=”{}”]Press Releases[/et_pb_text][/et_pb_column][/et_pb_row][/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.18.0″ _module_preset=”default” background_color=”#FFFFFF” custom_margin=”||-1px|||” custom_padding=”35px||55px|||” top_divider_height=”53px” top_divider_flip=”horizontal” bottom_divider_height=”47px” bottom_divider_flip=”horizontal” global_colors_info=”{}”][et_pb_row _builder_version=”4.18.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.18.1″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.2″ _module_preset=”default” text_font=”Lexend|500|||||||” text_text_color=”#010443″ text_font_size=”30px” text_line_height=”1.3em”
- [Products](https://mfx.bio/products-mfx-t/) - The MFX-T is our proprietary microfluidics-based bioreactor to help you get closer to your cells.
- [Technology](https://mfx.bio/technology/) - The Cyto Engine. Precise, scalable bioprocessing with complete integration of online PATs, powerful data visualisation and analysis
- [Jobs](https://mfx.bio/jobs/) - View our latest vacancies and join us in developing the next generation of bioprocessing platforms
- [Contact](https://mfx.bio/contact/) - We’re always looking to hear from you in regards to research, job opportunities and your next project.
- [Cookie Policy](https://mfx.bio/cookie-policy/) - microfluidx Cookie Policy
- [Old Products Page](https://mfx.bio/products/) - Next generation platforms for research and GMP manufacturing leveraging best-in-class cell culture, bio-analytical, data visualisation and mining technologies.
- [News-Blog](https://mfx.bio/blog/) - Read our latest blog articles on cell and gene therapy development and manufacturing, and what we do at MFX
- [MFX_Stemmatters_PR_26Oct2022](https://mfx.bio/news-press-releases/press-release-mfx-stemmatters-2022/) - Increasing the consistency and scalability of MSC expansion whilst retaining functionality and reducing costs
- [MFX_New Board_PR_28September2023](https://mfx.bio/news-press-releases/press-release-mfx-new-board-members-2023/) - Strengthening expertise in cell and gene therapy manufacturing and innovative technology development
- [MFX_InnovateUK_PR_119December2023](https://mfx.bio/news-press-releases/press-release-mfx-innovateuk-2023/) - MicrofluidX secures £1m funding via Innovate UK Investor Partnerships Future Economy programme, supported by Longwall Ventures
- [MFX_Immatics_PR_2May2023](https://mfx.bio/news-press-releases/press-release-mfx-immatics-2023/) - Joint research project with the goal of increasing efficiency and reducing cost of manufacture through precision process control
- [MFX_Funding_PR_8December2022](https://mfx.bio/news-press-releases/press-release-mfx-funding-2022/) - The funding will advance development of the Cyto Engine™ platform and enable new trials with end users
- [MFX_CCRM_PR_11January2023](https://mfx.bio/news-press-releases/press-release-mfx-ccrm-2023/) - MFX announces a partnership with CCRM
- [MFX_Anthony Nolan_PR_19June2023](https://mfx.bio/news-press-releases/press-release-mfx-anthony-nolan-2023/) - Anthony Nolan Cell Therapy and Laboratory Services is delighted to announce their newest partnership with start-up MicrofluidX.
- [Privacy Policy](https://mfx.bio/privacy-policy/) - microfluidx Privacy Policy
- [12_Data and digitization](https://mfx.bio/blog/blog-data-and-digitization/) - Goodbye paper. Digitizing data collection, analysis, and record keeping is the future of cell and gene therapies
- [11_PATs and large scale manufacturing of cell therapies](https://mfx.bio/blog/blog-pats-and-large-scale-cell-therapy-manufacturing/) - Without PATs, large-scale manufacturing of cell therapies isn't commercially viable
- [10_Scaling up microfluidics](https://mfx.bio/blog/blog-scaling-up-microfluidics/) - Can microfluidics really deliver clinically relevant numbers of cells for cell therapies?
- [09_Make your cells feel at home](https://mfx.bio/blog/blog-make-you-cells-feel-at-home-with-microfluidics/) - Are your cell culture vessels truly providing an optimal environment for cell expansion?
- [08_Microfluidics-the perfect meeting place](https://mfx.bio/blog/blog-microfluidics-the-perfect-meeting-place/) - Viral transduction is currently a high-cost, low-yield process with conventional bioreactors
- [07_Scale up look sharp](https://mfx.bio/blog/blog-scale-up-look-sharp/) - CGTs developers need better analytics in their manufacturing platforms to refine processes and characterize their product
- [06_Why successful cell therapy processes need to scale both ways](https://mfx.bio/blog/blog-why-successful-cell-therapy-processes-need-to-scale-both-ways/) - A process for manufacture that can't be scaled down isn't beneficial if pre-clinical development needs to be revisited
- [05_Is innovation in automation enough](https://mfx.bio/blog/blog-is-innovation-in-automation-enough/) - Robot arms and existing automated cell culture platforms won't be able to support the future needs of cell therapy manufacturing
- [04-Footprint size matters](https://mfx.bio/blog/blog-footprint-size-matters/) - As it stands, manufacturing capacity won't meet the expected demand of cell therapies in the next decade
- [01_99 problems in cell research](https://mfx.bio/blog/blog-99-problems-in-cell-research/) - Even the simple action of pipetting adds variability during manual cell processing
- [02_New technologies, old methods](https://mfx.bio/blog/blog-new-technologies-old-methods/) - Cell and gene therapy developers need to start thinking about scaling up earlier on in the process
- [03_How to ensure a consistent expansion process](https://mfx.bio/blog/blog-how-to-ensure-a-consistent-expansion-process/) - Relying on endpoints doesn't give a true representation of the cell expansion process
- [Data signup success](https://mfx.bio/data/data-signup-success/) - Thank you for your interest in our data. Find out more about the Cyto Engines for cell and gene therapy bioprocessing and manufacturing on our products page.

## Logos

- [CMaT](https://mfx.bio/logosliderwp/cmat/)
- [University of Oxford](https://mfx.bio/logosliderwp/university-of-oxford/)
- [UCL](https://mfx.bio/logosliderwp/ucl/)
- [Stemmatters](https://mfx.bio/logosliderwp/stemmatters/)
- [Stanford University](https://mfx.bio/logosliderwp/stanford-university/)
- [Immatics](https://mfx.bio/logosliderwp/immatics/)
- [CCRM](https://mfx.bio/logosliderwp/ccrm/)
- [Anthony Nolan](https://mfx.bio/logosliderwp/anthony-nolan/)
- [EU](https://mfx.bio/logosliderwp/eu/)
- [Innovate UK](https://mfx.bio/logosliderwp/252/)
- [UKRI](https://mfx.bio/logosliderwp/ukri/)
- [Kings College London](https://mfx.bio/logosliderwp/kings-college-london/)
- [VTT](https://mfx.bio/logosliderwp/vtt/)
- [CPI](https://mfx.bio/logosliderwp/cpi/)
- [Catapult](https://mfx.bio/logosliderwp/catapult/)

## Categories

- [Uncategorized](https://mfx.bio/category/uncategorized/)
- [Careers](https://mfx.bio/category/careers/)
- [Blog](https://mfx.bio/category/blog/)